EN DE
Check 35,000+ stocks against 26 valuation models and 37 quality factors
Data-driven stock valuation

Hangzhou Minsheng Healthcare Co Ltd (301507) fair value: what the stock is really worth

As of Sep 22, 2026: fair value of Hangzhou Minsheng Healthcare Co Ltd ¥4.28, price ¥13.33, upside -67.9%, quality 44 out of 100. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.

  1. Fair value above price? No
  2. Good quality? No
  3. Add to watchlist

Healthcare · CN · ISIN CNE1000068Q3

HM Some data Sep 23, 2026

Hangzhou Minsheng Healthcare Co Ltd

301507 · SHE

Weakest SetupStrongly overvalued and low quality.

!Fair value ¥4.28 · Strongly overvalued (−68%)
!Quality 44/100
!Expensive Growth (revenue 3y +12.6 %/yr)
✓Solidly profitable · 14.4% net margin (TTM)
!negative free cash flow
·1.13% dividend yield
!Trails peers (3/12)
!Moderate moat 55/100
!Evidence only medium, so the estimate is less certain
!Weak on past: 28 out of 100
!Weak on dividend: 23 out of 100
Watch Hangzhou Minsheng Healthcare Co Ltd for free, get notified when fair value or trend changes. Plus fair value for all 35,000+ stocks, 14 days of Pro free, no card. Watch for free Pro now: $1 first month

What runs behind every stock

26 valuation models 8 families, DCF to NCAV 37 quality factors margins, balance sheet, cashflow, debt 6 AI factors moat, what no ratio measures 2,000+ data points verified, per stock, median

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

¥31.88 ¥10.54 Fair Value ¥4.28 Sep 2023 Sep 2026

White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Sep 23, 2026.

How to read this chart

37‑month range ¥10.54 – ¥31.88 · fair‑value band ¥3.65 – ¥5.57 · the ¥13.33 price screens above the ¥4.28 fair value. Dashed = 300-day average. As of Sep 23, 2026.

Follow Hangzhou Minsheng Healthcare Co in your weekly email

Every Wednesday you see whether Hangzhou Minsheng Healthcare Co is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

Hangzhou Minsheng Healthcare Co., Ltd. engages in the research, development, production, and sale of vitamins and mineral supplements, OTC drugs, and health foods in China.

Show more

Hangzhou Minsheng Healthcare Co., Ltd. engages in the research, development, production, and sale of vitamins and mineral supplements, OTC drugs, and health foods in China. The company offers healthy products, such as fish and algae oil gel candy, collagen peptide vitamin D calcium chewable tablets, blueberry lutein ester candy tablets, and probiotic solid beverage. It also provides multivitamin, vitamin, and zinc selenium with mineral tablets; and glucosamine chondroitin colostrum protein chewable, vitamin soft capsules and chewable, iron folic acid, melatonin, coenzyme soft capsules, and calcium magnesium vitamin D tablets. The company offers its product under the 21 SUPER-VITA brand name. Hangzhou Minsheng Healthcare Co., Ltd. was founded in 1926 and is based in Hangzhou, China.

Stock analysis

Hangzhou Minsheng Healthcare Co Ltd (301507) currently trades at ¥13.33, while our model-based Fair Value estimate is ¥4.28, implying the stock looks roughly 211.4% overvalued today.

Show more

Valuation

Bull case: the Growth Earnings group reads highest at a median of ¥6.77 per share, and 0 of the 14 models we run sit above the ¥13.33 price.

Bear case: the Economic Profit group reads lowest at ¥2.96, and 14 of the 14 models stay below the price. Evidence for this calculation is medium.

Scenario range: ¥3.65 (bear) to ¥5.57 (bull), the price of ¥13.33 sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 44/100 (below-average quality), in the Healthcare sector.

Expensive Growth: The company is growing, but growth may require heavy reinvestment or weak cash conversion.

Hangzhou Minsheng Healthcare Co Ltd reported revenue of 782M CNY in FY2025 versus 490M CNY in FY2021, a compound +12.4%/yr. Reported net income was 119M CNY in FY2025, compounding +14.0%/yr from FY2021.

Key figures

Market cap 4.8B CNY (≈ $710M) · P/E ratio 40.4 · P/S ratio 6.14 · EPS (TTM) ¥0.3300 · Dividend yield 1.1% · Net margin 15.2% · Return on equity 7.0% · Return on assets (EBIT) 7.2%.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 48 out of 100 (low confidence).

What moves the price

The share trades about 24% below its 52-week high and 16% above its 52-week low, currently below its 200-day average.

For context, the median of 10 Healthcare peers we cover trades at −2% fair-value upside, at −68%, 301507 screens richer than that median.

Fair Value models

Bear ¥3.65 Fair Value ¥4.28 Bull ¥5.57
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model. Based on fiscal year 2025 figures (about 9 months old). Earnings retained since then (¥0.1317 per share) are deliberately not added. Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Highest evidence
Residual Income ¥3.62 ¥3.81 ¥4.10 73
EPV ¥2.66 ¥2.96 ¥3.21 68
ROIC Compounder ¥2.66 ¥2.96 ¥3.21 67
All 14 models by family
Earnings-Based
Graham-Dodd ¥2.27 ¥11.15 ¥15.37 61
Lynch FV ¥3.00 ¥4.28 ¥5.57 58
PEG = 1.0 ¥3.00 ¥4.28 ¥5.57 55
EPV ¥2.66 ¥2.96 ¥3.21 68
Multiples
P/E Multiple ¥5.50 ¥7.33 ¥9.16 63
P/S Multiple ¥4.25 ¥5.66 ¥7.08 58
P/B Multiple ¥4.25 ¥5.66 ¥7.08 55
EV/EBIT ¥4.10 ¥5.19 ¥6.29 63
EV/EBITDA ¥4.38 ¥5.56 ¥6.75 64
EV/Revenue ¥3.16 ¥4.16 ¥5.17 52
Asset-Based
NCAV (Graham) ¥2.24 ¥3.00 ¥4.48 51
Economic Profit
Residual Income ¥3.62 ¥3.81 ¥4.10 73
ROIC Compounder ¥2.66 ¥2.96 ¥3.21 67
Growth Earnings
Growth-Adj P/E ¥4.74 ¥6.77 ¥8.80 65

Open the full fair value analysis →

Notify me when 301507 reaches fair value

Put 301507 on your watchlist. We get in touch as soon as price and fair value meet or the trend turns.

Set up alert →

Quality Score breakdown

Overall quality 44/100

Of which business quality 47 · Market factors (momentum, volatility) 47

Profitability 41
Margins and returns on capital today
Quality Growth 52
Are margins and returns improving?
Cashflow 38
Earnings quality: real cash, not paper profit
Fin. Strength 90
Balance sheet, leverage, solvency risk
Investment 0
Disciplined investing over empire-building
Low Volatility 77
Calm price path (market factor)
Momentum 39
Price trend over the last 3–12 months (market factor)
52W Momentum 28
Distance to the 52-week high (market factor)
Net Issuance 40
Share count: buybacks or dilution?

Open the full quality analysis →

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 54/100
The company is growing, but growth may require heavy reinvestment or weak cash conversion.
Revenue growth 1 year
+21.9%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+12.6%
What shareholders gained per year (last 5 years) ⓘWhat the business itself delivers per year: earnings growth per share plus the dividend yield. This is what you get IF the market keeps valuing the stock the same way: it contains no assumption about the market changing its mind. Computed per share, so buybacks count and a merger does not pass as growth. For a company that pays no dividend it is pure earnings growth per share. Period: earnings growth per share as CAGR over the last 5 reported fiscal years (annual statements), plus the current dividend yield. The start value is the median of the three years around the start, so a single crisis year (a pandemic or a write-down) does not distort the rate.
+6.0%
Earnings growth per share plus dividend.
Earnings per share, growth per year+4.9%
Dividend (yield on the price)1.1%
Profit margin 2021 to 2025 ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.14% → 12%

301507 screens 211% overvalued. Compare with Eli Lilly and Company →

Compare Hangzhou Minsheng Healthcare Co Ltd with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Drug Manufacturers - General · 71 stocks

Beats the industry median on 3/12 measures
Overall it trails its industry peers.
Valuation
Quality Score 44 · Bottom 25%
Fair Value upside −68% · Bottom 25%
Profitability
Return on equity (TTM) 7% · Below median
Return on assets 3% · Below median
Net margin (TTM) 14% · Above median
Operating margin (TTM) 24% · Above median
Growth and dividend
Revenue growth 17% · Top 25%
Dividend yield (TTM) 1.1% · Bottom 25%

Valuation Multiplesvs Drug Manufacturers - General median · lower = cheaper

P/E (TTM) 40.4× · Priciest 25%
P/B 2.97× · Pricier than median
P/S (TTM) 5.74× · Pricier than median
EV/EBITDA 36.5× · Priciest 25%

Strength profile in five axes (Snowflake)

VALUEFUTUREPASTHEALTHDIVIDEND
This stock
VALUEFUTUREPASTHEALTHDIVIDEND
Sector peers
VALUE (fair-value potential)0 · sector 18
FUTURE (revenue growth)85 · sector 29
PAST (return on equity)28 · sector 52
HEALTH (low debt)0 · sector 92
DIVIDEND (yield)23 · sector 41

VALUE 0: the price sits above our fair-value range.

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Drug Manufacturers - General stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value
Eli Lilly and Company LLY $1,170 $791.40 −32%
Johnson & Johnson, JNJ $269.19 $169.04 −37%
AbbVie Inc ABBV $265.21 $259.66 −2%
Roche Holding RO CHF 375.20 CHF 329.11 −12%
Merck & Co MRK $150.91 $129.12 −14%
Novartis AG NOVN CHF 116.46 CHF 119.10 +2%
Amgen Inc AMGN $410.24 $451.26 +10%
Gilead Sciences, Inc GILD $152.67 $198.51 +30%
Pfizer Inc PFE $27.93 $24.87 −11%
Bristol-Myers Squibb Company BMY $62.25 $75.98 +22%

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued High-Quality StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend Stocks

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names ⭐ Top Rated 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

Stock screenerFilter by region, size and sector Compare toolTwo stocks side by side Extrinsic Value Calculator…Calculator with industry benchmark Peter Lynch Fair Value Formula &…Calculator with industry benchmark
Run the numbers yourself: free valuation calculators
DCF CalculatorGraham NumberPeter Lynch FormulaDDM CalculatorFama-French ModelIntrinsic Value
For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

Hangzhou Minsheng Healthcare Co Ltd · Fair Value
¥4.28 −211%Fair Value
Calculator →

Cite: Fair Value Calculator (2026). "Hangzhou Minsheng Healthcare Co Ltd Fair Value". https://www.fairvalue-calculator.com/stock/301507

Frequently asked questions

Is Hangzhou Minsheng Healthcare Co Ltd (301507) overvalued or undervalued?
As of Sep 23, 2026, our model estimates a fair value of ¥4.28 versus a price of ¥13.33, about −68% upside (overvalued).
What is the fair value of 301507?
Our model-based fair value for Hangzhou Minsheng Healthcare Co Ltd is ¥4.28 (as of Sep 23, 2026), built from audited fundamentals. The current price: ¥13.33.
What is the quality score of 301507?
Hangzhou Minsheng Healthcare Co Ltd has a Quality Score of 44/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Hangzhou Minsheng Healthcare Co Ltd (301507)?
Our model-based price target is the fair value of ¥4.28 (as of Sep 23, 2026) from 14 valuation models. Cautious scenario ¥3.65, optimistic scenario ¥5.57. It is a calculation from audited fundamentals, not an analyst target.
What is the Hangzhou Minsheng Healthcare Co Ltd stock forecast for 2026?
Our models put fair value at ¥4.28, about −68% upside versus a price of ¥13.33 (overvalued). Cautious scenario ¥3.65, optimistic scenario ¥5.57. The calculation is refreshed regularly with new filings.
What is the revenue of Hangzhou Minsheng Healthcare Co Ltd (301507)?
Hangzhou Minsheng Healthcare Co Ltd reported trailing-twelve-month revenue of about 828M CNY (latest available figure, as of Sep 23, 2026).
Does Hangzhou Minsheng Healthcare Co Ltd pay a dividend?
Hangzhou Minsheng Healthcare Co Ltd currently shows a dividend yield of about 1.13% relative to its recent price (as of Sep 23, 2026).
What is the intrinsic value of Hangzhou Minsheng Healthcare Co Ltd (301507)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Hangzhou Minsheng Healthcare Co Ltd it is ¥4.28 per share (as of Sep 23, 2026), against a price of ¥13.33. It is the blended result of 14 valuation models (cash flow, earnings, asset, dividend).
Is Hangzhou Minsheng Healthcare Co Ltd stock overvalued or undervalued in 2026?
As of Sep 23, 2026, 301507 trades above its calculated fair value: price ¥13.33, fair value ¥4.28, a gap of about −68% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of 301507?
No. The price is what the market pays today (¥13.33); the fair value is what the company's own numbers justify (¥4.28). For Hangzhou Minsheng Healthcare Co Ltd the two are ¥9.05 per share apart. That gap is exactly why we show both numbers side by side.
How much is Hangzhou Minsheng Healthcare Co Ltd worth?
The market values Hangzhou Minsheng Healthcare Co Ltd at about 4.8B CNY (market capitalisation, as of Sep 23, 2026). Per share that is ¥13.33; our models calculate a fair value of ¥4.28 per share.
What do the bullish and bearish scenarios say about 301507?
Our models span a range for Hangzhou Minsheng Healthcare Co Ltd: cautious scenario ¥3.65, base ¥4.28, optimistic ¥5.57 per share (as of Sep 23, 2026, price ¥13.33). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the P/E ratio of 301507?
Hangzhou Minsheng Healthcare Co Ltd trades at a price-to-earnings ratio of 40.4 (as of Sep 23, 2026). A P/E on its own says little: it compares the price with ONE year of profit, while our fair value of ¥4.28 is built from several models across several years. Other multiples: P/B 3.0, P/S 5.7, EV/EBITDA 36.5.
How solid is the balance sheet of Hangzhou Minsheng Healthcare Co Ltd (301507)?
Balance-sheet figures for Hangzhou Minsheng Healthcare Co Ltd (as of Sep 23, 2026): return on equity 7.0%. They feed the Quality Score of 44/100, which measures business quality independently of the share price.
How far is 301507 from its 52-week high?
Hangzhou Minsheng Healthcare Co Ltd trades at ¥13.33, about 24% below its 52-week high of ¥17.57 and 16% above the low of ¥11.45 (as of Sep 22, 2026). Distance from the high says nothing about value: that is what the fair value of ¥4.28 is for.
Which stocks are comparable to Hangzhou Minsheng Healthcare Co Ltd?
From the same area (Healthcare) we also value Eli Lilly and Company, Johnson & Johnson,, AbbVie Inc, Roche Holding, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Hangzhou Minsheng Healthcare Co Ltd stock attractive at the current price?
The data as of Sep 23, 2026: price ¥13.33, calculated fair value ¥4.28 (−68%), Quality Score 44/100, from 14 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of 301507 calculated?
We run Hangzhou Minsheng Healthcare Co Ltd through 14 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of ¥4.28, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 14.1 % above its aggregate fair value. Hangzhou Minsheng Healthcare Co Ltd itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Hangzhou Minsheng Healthcare Co Ltd (301507)?
The closing price on Sep 22, 2026 was ¥13.33. Our model-based fair value is ¥4.28, about −68% upside (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Hangzhou Minsheng Healthcare Co Ltd right now?
The price sits above even our optimistic bull case (¥5.57). The favourable scenario is already priced in. Weak quality (44/100) and above fair value at the same time, the margin of safety is missing on both counts.

Key figures of Hangzhou Minsheng Healthcare Co Ltd

How large is the market capitalisation of Hangzhou Minsheng Healthcare Co Ltd (301507)?
The market capitalisation of Hangzhou Minsheng Healthcare Co Ltd is 4.8B CNY (≈ $710M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Hangzhou Minsheng Healthcare Co Ltd (301507)?
The price-to-sales ratio of Hangzhou Minsheng Healthcare Co Ltd is 6.14 (P/E × margin). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Hangzhou Minsheng Healthcare Co Ltd (301507)?
Earnings per share at Hangzhou Minsheng Healthcare Co Ltd are ¥0.3300 (price ÷ EPS = P/E 40.4). Earnings per share over the last twelve months: total profit spread across every single share.
What is the dividend yield of Hangzhou Minsheng Healthcare Co Ltd (301507)?
The dividend yield of Hangzhou Minsheng Healthcare Co Ltd is 1.1% (payout 45.5%). Yearly dividend relative to the share price. 3% pays 3 per 100 invested. Below: how much of profit is used for it.
What is the net margin of Hangzhou Minsheng Healthcare Co Ltd (301507)?
The net margin of Hangzhou Minsheng Healthcare Co Ltd is 15.2% (fiscal year 2025). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Hangzhou Minsheng Healthcare Co Ltd (301507)?
The return on equity (ROE) of Hangzhou Minsheng Healthcare Co Ltd is 7.0% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Hangzhou Minsheng Healthcare Co Ltd (301507)?
On an EBIT basis the return on assets of Hangzhou Minsheng Healthcare Co Ltd is 7.2% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Hangzhou Minsheng Healthcare Co Ltd (301507)?
The operating margin of Hangzhou Minsheng Healthcare Co Ltd is 24.3% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Hangzhou Minsheng Healthcare Co Ltd (301507)?
Revenue at Hangzhou Minsheng Healthcare Co Ltd is growing +17.0% versus a year earlier (3y avg +12.6%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at Hangzhou Minsheng Healthcare Co Ltd (301507)?
Earnings per share at Hangzhou Minsheng Healthcare Co Ltd are growing +0.2% versus a year earlier. How much earnings per share grew versus a year earlier.
How much free cash flow does Hangzhou Minsheng Healthcare Co Ltd (301507) generate?
The free cash flow of Hangzhou Minsheng Healthcare Co Ltd is −19.2M CNY (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
Free · no account needed

Watch Hangzhou Minsheng Healthcare Co Ltd in the live analysis

One click puts Hangzhou Minsheng Healthcare Co Ltd on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.